Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Other 1NET 1Gastrointestinal 1CNS 1

Conditions

Pituitary Diseases 1Obesity 1Neoplasms 1Hyperinsulinism 1Craniopharyngioma 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Lomustine 36Ipilimumab 36Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Diazoxide × CNS × Clear all
NCT00306683 2011-02-18

Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed
40 enrolled
CNSEndocrineOther

Craniopharyngioma, Hyperinsulinism, Neoplasms, Obesity, Pituitary Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡